#United States #New York #Class Action #Gross Law Firm #Merck

Recent Notice for Merck Shareholders

On March 3, 2025, The Gross Law Firm shared important information crucial for shareholders of Merck & Co., Inc. (NYSE: MRK). The notice invites those who acquired shares within the specified class period to reach out regarding their potential role as lead plaintiffs in a class action lawsuit. Notably, registering as a lead plaintiff is not a prerequisite for participating in any recovery from the case.

Details of Class Period and Allegations

The designated class period is confined to the dates from February 3, 2022, to February 3, 2025. The allegations arise from what the firm describes as misleading information provided to investors concerning projected revenue figures for Merck’s vaccine Gardasil. The lawsuit posits that Merck had projected sales of $11 billion by the year 2030. Specific statements indicated confidence that effective consumer engagement and educational initiatives would significantly boost demand, particularly in the Chinese market.

However, this optimistic outlook shifted dramatically on February 4, 2025. Merck disclosed that it would be halting shipments of Gardasil to China until at least mid-year, a decision driven by excessive inventories that did not align with expectations of demand recovery. Following this announcement, the market reacted sharply; Merck's stock plummeted more than 9%, dropping from $99.79 to $90.74 per share in just one day.

Critical Deadlines and Next Steps

Shareholders are urged to act quickly in registering their information for this class action, with the imperative deadline approaching on April 14, 2025. After registering, shareholders will automatically join a portfolio monitoring system that offers status updates throughout the case’s lifecycle. Notably, participation in this case incurs no costs or obligations for any shareholder.

Why Choose Gross Law Firm?

The Gross Law Firm stands as a notable advocate for investors, specializing in class-action lawsuits. Their mission focuses on safeguarding the rights of those adversely affected by dishonest business practices. The firm is dedicated to ensuring companies uphold ethical standards and corporate responsibility. They seek compensation for investors significantly impacted by inaccurate or misleading company statements.

Contact Information

For further inquiries or to ensure your participation in this class action, you may contact The Gross Law Firm at: 15 West 38th Street, 12th floor, New York, NY, 10018. They can be reached at (646) 453-8903 or via email at [email protected].

This notice serves as a reminder for all affected shareholders to participate actively in this crucial legal process and to remain informed of the developing situation surrounding Merck’s financial disclosures and expected sales figures.